Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
25420
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings summaryFiscal year ending September 202612 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales46,910 Millions of yen+120.0%
Operating profit807 Millions of yen+180.0%
Ordinary income748 Millions of yen+240.0%
Net income346 Millions of yen+230.0%
Gross Profit Margin
Rate4Q 15.2%
Results for the three months of the current quarter
Net Sales
10,726 Millions of yen
Operating profit
163 Millions of yen
Gross Margin15.2%
Full-year earnings forecast
Fiscal year ending September 2027
Net Sales
48,000 Millions of yen
Operating profit
900 Millions of yen
Ordinary income
850 Millions of yen
Net income
500 Millions of yen
EBITDA
1,464 Millions of yen
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Results were slightly below the latest assumptions but exceeded the revised outlook issued in May.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Impact of higher revenue+¥130 million
- Change in gross margin-¥120 million
- Change in personnel expenses-¥40 million
- Change in other SG&A expenses-¥30 million
- Non-operating income and expenses-¥110 million
- Integration of the ファスキアグループ+¥930 million
- Amortization of goodwill and other items-¥270 million
- Stock acquisition-related expenses-¥50 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Revenue from new construction, expansion and renovation projects in the fiscal year ending September 2027¥95 100 million
- Company-wide gross margin12.7%NoteAssumes a 0.4 percentage-point decline from the previous fiscal year
- Large projects of ¥2 billion or more1 projects
- Projects below ¥1 billion17 projects
New initiatives
- Established a voluntary nomination and compensation committee in October 2026
- Continue considering growth investment through further alliances and equity investments
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA1,376 Millions of yenYear on year against the same period last year3.6x
- 4Q gross margin15.2 %Year on year against the same period last year+3.5 percentage points versus 3Q
- Equity ratio25.7 %
- ROE6.0 %Year on year against the same period last yearIncreased
- PBRApproximately 1x
Unit price and quantity metricsThese figures show sales broken down by price and volume.
New construction, expansion and renovation projects
Revenue for the fiscal year ending September 2027
9,488 Millions of yen
Number of Cases18
Average ticket
527 Millions of yen
Bulk sales as a percentage of business revenue41.8%
Segment results
- Total Medical SolutionsNet Sales21,283 Millions of yenYear-on-year revenue growth+5.1%Operating profit249 Millions of yenYear-on-year change in operating profit-19.0%
- Teleradiology ServicesNet Sales821 Millions of yenYear-on-year revenue growth-0.0%Operating profit66 Millions of yenYear-on-year change in operating profit-4.5%
- Minimally Invasive Medical Device SalesNet Sales22,279 Millions of yenOperating profit381 Millions of yen
- RentalsNet Sales638 Millions of yenOperating profit81 Millions of yen
- OtherNet Sales1,886 Millions of yenOperating profit93 Millions of yen
Medium-term management plan targets
Average for the fiscal years ending September 2031–2033
Net Sales50,000 Millions of yen
Gross Margin14%
Comparison with actual resultsThe company plans revenue of ¥48.5 billion for the fiscal year ending September 2027, with achievement ahead of schedule also in view.
Financial targets
Actual ROE6.0%
Relationship to the cost of equityStill below the cost of shareholders’ equity
Number of employees
Number of Employees361 people
Average number of temporary employees141 people
Annual Dividend
Fiscal year ending September 2026
Per share17 Yen
Fiscal year ending September 2027
Per share22 Yen
Payout ratio
Fiscal year ending September 202629%
Fiscal year ending September 202726%
Guideline20–30% on a consolidated basis
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings summary |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Net Sales | 46,910 Millions of yen (YoY +120.0%) |
| Operating profit | 807 Millions of yen (YoY +180.0%) |
| Ordinary income | 748 Millions of yen (YoY +240.0%) |
| Net income | 346 Millions of yen (YoY +230.0%) |
| Gross Profit Margin | Rate 4Q 15.2% / Year-on-year change (points) Not disclosed |
| Results for the three months of the current quarter | Net Sales 10,726 Millions of yen / Operating profit 163 Millions of yen / Gross Margin 15.2% |
| Full-year earnings forecast | Fiscal year ending September 2027 Net Sales 48,000 Millions of yen / Operating profit 900 Millions of yen / Ordinary income 850 Millions of yen / Net income 500 Millions of yen / EBITDA 1,464 Millions of yen |
| Self-assessment against the plan | Results were slightly below the latest assumptions but exceeded the revised outlook issued in May. |
| Segment results | Segment Total Medical Solutions / Net Sales 21,283 Millions of yen / Year-on-year revenue growth +5.1% / Operating profit 249 Millions of yen / Year-on-year change in operating profit -19.0%, Segment Teleradiology Services / Net Sales 821 Millions of yen / Year-on-year revenue growth -0.0% / Operating profit 66 Millions of yen / Year-on-year change in operating profit -4.5%, Segment Minimally Invasive Medical Device Sales / Net Sales 22,279 Millions of yen / Operating profit 381 Millions of yen, Segment Rentals / Net Sales 638 Millions of yen / Operating profit 81 Millions of yen, Segment Other / Net Sales 1,886 Millions of yen / Operating profit 93 Millions of yen |
| Breakdown of Factors Affecting the Change | Factors Impact of higher revenue / Amount +¥130 million, Factors Change in gross margin / Amount -¥120 million, Factors Change in personnel expenses / Amount -¥40 million, Factors Change in other SG&A expenses / Amount -¥30 million, Factors Non-operating income and expenses / Amount -¥110 million, Factors Integration of the ファスキアグループ / Amount +¥930 million, Factors Amortization of goodwill and other items / Amount -¥270 million, Factors Stock acquisition-related expenses / Amount -¥50 million |
| Key KPIs | Indicator name EBITDA / Value 1,376 Millions of yen / Year on year against the same period last year 3.6x, Indicator name 4Q gross margin / Value 15.2 % / Year on year against the same period last year +3.5 percentage points versus 3Q, Indicator name Equity ratio / Value 25.7 % / Year on year against the same period last year Not disclosed, Indicator name ROE / Value 6.0 % / Year on year against the same period last year Increased, Indicator name PBR / Value Approximately 1x / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | New construction, expansion and renovation projects Revenue for the fiscal year ending September 2027 9,488 Millions of yen / Number of Cases 18 / Average ticket 527 Millions of yen / Bulk sales as a percentage of business revenue 41.8% |
| Number of employees | Number of Employees 361 people / Average number of temporary employees 141 people |
| Assumptions Underlying the Business Outlook | Item Revenue from new construction, expansion and renovation projects in the fiscal year ending September 2027 / Value ¥95 100 million, Item Company-wide gross margin / Value 12.7% / Note Assumes a 0.4 percentage-point decline from the previous fiscal year, Item Large projects of ¥2 billion or more / Value 1 projects, Item Projects below ¥1 billion / Value 17 projects |
| Medium-term management plan targets | Average for the fiscal years ending September 2031–2033 Net Sales 50,000 Millions of yen / Gross Margin 14% / Comparison with actual results The company plans revenue of ¥48.5 billion for the fiscal year ending September 2027, with achievement ahead of schedule also in view. |
| Financial targets | Actual ROE 6.0% / Relationship to the cost of equity Still below the cost of shareholders’ equity |
| Annual Dividend | Fiscal year ending September 2026 Per share 17 Yen / Fiscal year ending September 2027 Per share 22 Yen |
| Payout ratio | Fiscal year ending September 2026 29% / Fiscal year ending September 2027 26% / Guideline 20–30% on a consolidated basis |
| New initiatives | Established a voluntary nomination and compensation committee in October 2026, Continue considering growth investment through further alliances and equity investments |
Items this document does not state (10)
Operating profit marginSelling, general and administrative expensesProgress against full-year forecastNumber of stores and locationsRisk amount incorporated into the outlookAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue and profit for the fiscal year ended September 2026 was largely attributable to the consolidation of the ファスキア group, which engages in businesses including the sale of minimally invasive medical devices. The shortfall against the latest assumptions resulted from revenue recognition differing from expectations for certain projects. The expected increase in profit for the fiscal year ending September 2027 is mainly attributable to the revenue contribution from large-scale new construction, expansion and renovation projects and a decrease in M&A-related expenses recorded in the previous fiscal year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.